Nasdaq · Healthcare

Autolus Therapeutics plc (AUTL)

As-reported financials and recent SEC filings for Autolus Therapeutics plc, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$75.4M

Net income

$-287.5M

Net margin

—

Diluted EPS

$-1.08

ROE

-161.4%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$75.4M	$10.1M	$1.7M	—	—
Gross profit	$-21.0M	$-1.3M	—	—	—
Operating income	$-270.5M	$-241.4M	$-179.7M	$-143.4M	$-141.1M
Net income	$-287.5M	$-220.7M	$-208.4M	$-148.8M	$-142.1M
Diluted EPS	$-1.08	$-0.86	$-1.20	$-1.57	$-1.97

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-07-01

42026-07-01

42026-07-01

42026-07-01

42026-07-01

42026-07-01

42026-07-01

42026-07-01

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on AUTL

Search Autolus Therapeutics plc’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.